Compare Ginkgo Bioworks Holdings Inc (DNA) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Gartner Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $515.15M), while Gartner Inc trades at $187.27 (market cap $12.20B). The key difference: Gartner Inc is far larger — about 23.7× Ginkgo Bioworks Holdings Inc's market cap, and Gartner Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | IT | |
|---|---|---|
Market Cap | $515.15M | $12.20B |
Sector | Health | Technology |
52-Week High | $16.14 | $264.09 |
52-Week Low | $5.48 | $125.68 |
Enterprise Value | $617.10M | $13.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
Gartner (IT) trades at $185.6, up 0.42% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 69.63% gross margin and 12% net income margin, though revenue growth has moderated. Recent news highlights Q2 2026 earnings exceeding expectations and raised full-year EPS guidance, driving positive investor sentiment.
Outlook is supported by valuation discounts (P/E 16.69) and high ROE (113.58%), but risks include consulting segment weakness and negative net cash flow trends. Analysts are mixed with a $172.80 consensus target, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
